

Full Title: Strategies to Reduce Hyperglycemia-Related Anxiety in Elite Athletes with Type 1 Diabetes:

A Qualitative Analysis

Running Title: Hyperglycemia-Related Anxiety: Athletes w/ T1D

Authors: Alexandra Katz, MSc (ORCID: 0000-0002-7137-6393)^{1,2,3}, Aidan Shulkin (ORCID: 0009-0000-1525-0350)¹, Marc-André Fortier, RD², Jane E. Yardley, PhD (ORCID: 0000-0001-8761-7019)^{3,4}, Jessica Kichler, PhD (ORCID: 0000-0003-0133-0194)⁵, Asmaa Housni, RD (ORCID: 0000-0002-6007-9641)², Meryem K. Talbo, RD (ORCID: 0000-0002-7717-3335)², Rémi Rabasa-Lhoret, MD, PhD (ORCID: 0000-0003-4706-5170)^{1,3,6}, Anne-Sophie Brazeau, RD, PhD (ORCID: 0000-0002-2699-2920)²

¹Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada;

²School of Human Nutrition, McGill University, Montreal, Québec, Canada;

³Institut de Recherches Cliniques de Montréal, Montréal, Québec, Canada;

⁴École de kinésiologie et des sciences de l'activité physique, Université de Montréal, Montréal, Québec, Canada;

⁵Department of Psychology, University of Windsor, Windsor, Ontario, Canada;

⁶Service d'endocrinologie du Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Québec, Canada.

Contact Information of Corresponding Author: Brazeau, Anne-Sophie (anne-

sophie.brazeau@mcgill.ca)

Abstract Word Count: 250

Manuscript Word Count: 4027

Number of Tables: 0

Number of Figures: 2

Keywords: Type 1 Diabetes, Physical Activity, Hyperglycemia, Elite Athletes, Anxiety.

Abstract

Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. Hyperglycemia-related anxiety (HRA) likely affects performance and diabetes management, but research is limited. This study investigates current strategies employed to mitigate HRA during competition and the development of alternative approaches.

Research Design and Methods: Elite athletes with T1D, aged ≥ 14 who self-reported HRA during competition were recruited. Elite athletes were defined as individuals exercising >10 hours per week whose athletic performance has achieved the highest competition level. 60 to 90-minute virtual semi-structured interviews were analyzed using an Interpretative Phenomenological Analysis.

Results: Ten elite athletes with T1D (average age 25 ± 3 years; T1D duration 12 ± 8 years; # of competitions per year 27 ± 19 ; training time per week 12 ± 6 hours) reported the strategies they currently use to mitigate HRA. These strategies include managing insulin and nutrition intake, embracing social support networks, using technology, practicing relaxation techniques, establishing routines, performing pre-competition aerobic exercise, and maintaining adequate sleep hygiene. Several additional approaches that could be implemented were identified including establishing targeted support networks, developing peer-reviewed resources on HRA, ensuring support teams have sufficient tools, and improving existing technology.

Conclusions: Elite athletes with T1D use physiological and psychological strategies to mitigate HRA during competition. This finding highlights the need for increased support and education for these athletes, and advancements in technology. Targeted strategies and personalized approaches are also needed to optimize performance and diabetes management in this population.

Introduction

Individuals with type 1 diabetes (T1D) compete at the highest level of their sports, including winning Olympic gold medals and becoming professional athletes [1]. However, participating in physical activity (PA) poses considerable challenges for athletes with T1D, primarily due to its multifaceted influence on glycemia [2-5]. T1D is an autoimmune disorder in which the insulin-producing beta cells of the pancreas are destroyed, leading to a significant reduction or complete cessation of insulin production. Incorrect management of blood glucose (BG) modifiers, including insulin, pre-competition meal composition, exercise duration and intensity, stress levels, and sleep quality can lead to dangerous fluctuations in BG levels which can result in hyper- or hypoglycemia [6, 7].

Most people with T1D prioritize avoiding hypoglycemia during PA as it can compromise performance [16] due to lack of concentration, headaches, dizziness, and confusion [17]. Conversely, athletes may also worry about hyperglycemia, which can also reduce performance through debilitating symptoms such as shortness of breath, thirst, slower reaction time, and blurred vision [3, 11].

Fear of hypoglycemia during PA is well documented [9], however, research on hyperglycemia-related anxiety (HRA) is limited. Hyperglycemia is often considered a chronic condition, with its acute symptoms typically causing minimal disruption to daily life [10]. However, any element that hinders competition performance in elite athletes is a significant concern [11]. Various factors, including competition-associated stress may cause hyperglycemia [2, 12, 13]. A position statement from the *National Athletic Trainers' Association* [14] acknowledges that high anticipatory stress can elevate counterregulatory hormones, such as adrenaline and cortisol, potentially increasing BG before and during competition [9]. This specifically affects elite athletes, as they face increased amounts of performance-related stress and anxiety [8].

Current recommendations for diabetes management are not adapted to the specific physiological and psychological demands of competition [13, 15]. For example, athletes who expect a BG rise before competition are more prone to taking preventive measures (e.g., injecting more insulin, and limiting pre-PA carbohydrate intake) [2].

A recent case study suggests a need for tailored treatment programs for elite athletes with T1D [11], but there is limited information available in the scientific literature and none exploring HRA. Therefore, this study aims to understand the impact that HRA has on competition and diabetes management among elite athletes with T1D. Additionally, it explores the strategies used by these athletes to prevent HRA during competition and maps out additional approaches that they can use to optimize BG management.

Methods

Study Design, Participants & Recruitment

This cross-sectional qualitative analysis was conducted following the Consolidated Criteria for Reporting Qualitative Research checklist [18]. Ethics approval was obtained by the Centre Hospitalier de l'Université de Montréal ethics committee (2024-11786 (23.156)). Individuals were eligible to participate in this study if they were elite athletes ≥ 14 years old, had a T1D diagnosis for ≥ 1 year, self-reported HRA during competition, used intensive insulin therapy, and spoke English or French. Participants were excluded if they had a diagnosis of Generalized Anxiety Disorder (GAD) or a score of >10 on the GAD 7-item scale [19]. Elite athletes were defined as individuals exercising >10 h/week whose athletic performance had achieved the highest competition level (definition based on [20]). HRA was defined as the feelings of worry, fear, or distress that individuals with T1D had in relation to hyperglycemia. Recruitment was conducted via word-of-mouth, at the Montreal Clinical Research Institute (IRCM) clinic, and by internet postings (e.g., newsletters, websites, social media, etc.). Potential participants were screened for eligibility, consented to participation, filled out a demographic questionnaire, and registered for an interview via the Research Electronic Data Capture (REDCap) tool [21].

Interviews

Semi-structured individual interviews were scheduled for 60-90 minutes on Microsoft Teams and were conducted in English or French. To enhance the understanding of participant perspectives and acknowledge the potential impact of the researcher's positionality, the research team employed bracketing, defined as the

systematic suspension of preconceptions and biases during data collection and analysis [22]. A research team member followed an interview discussion guide (Figure 1) to direct the open-ended conversation using five probing and additional prompting questions derived from the *Hyperglycemia Avoidance Scale* [23]. The guide was reviewed by a multidisciplinary team including dietitians, an endocrinologist, a clinical psychologist, a kinesiologist, and a patient partner. Before the interview, participants were given the probing questions to reflect on. Additional resources were available for mental health support if necessary.

Figure 1. Interview Discussion Guide

Interview Discussion Guide
<p>Probing Question 1:</p> <ul style="list-style-type: none">- What impact, if any, has T1D had on your physical activity, in general?
<p>Prompting Questions:</p> <ul style="list-style-type: none">- How has T1D affected your capabilities as an athlete, if at all?- How has T1D affected your ability to participate in physical activity, if at all?- How does hypoglycemia impact physical activity and performance for you, if at all?- How does your T1D management differ/not differ when participating in competition vs. training?
<p>Probing Question 2:</p> <ul style="list-style-type: none">- What impact, if any, has hyperglycemia had on your competition performance?
<p>Prompting Questions:</p> <ul style="list-style-type: none">- How does hyperglycemia during competitions impact your overall performance, if at all?- How would you describe your physical reaction(s) if/when you experience hyperglycemia during competitions?- How would you describe your emotional reaction(s) if/when you experience hyperglycemia during competitions?
<p>Probing Question 3:</p> <ul style="list-style-type: none">- What strategies, if any, do you use to prevent hyperglycemia and how effective do you find them to be?
<p>Prompting Questions:</p> <ul style="list-style-type: none">- What strategies or techniques do you currently use to prevent hyperglycemia during competitions (ex. changes in eating behaviors, medication, etc.), if any? How effective have they been for you, and what challenges have you encountered while implementing them?- How do you prioritize between achieving optimal blood glucose levels and performing at your best during competitions? How do you find the right balance?- What interventions, support, or technologies, if any, could be implemented to reduce the frequency of impact of hyperglycemia during competition for elite athletes with T1D, in general? This can include education, technology/CGM, nutrition, and/or insulin-related strategies.

Probing Question 4:

- How would you describe any hyperglycemia-related anxiety symptoms you may experience?

Prompting Questions:

- What physical, emotional, and/or behavioral symptoms do you experience during these times, if any? (e.g., racing heart, fast breathing)

- How does hyperglycemia-related anxiety impact your physical activity and/or performance during competition, if at all?

- How do your hyperglycemia-related anxiety symptoms influence your diabetes management strategies before, during, and after competitions, if at all?

Probing Question 5:

- Please describe any specific instances where hyperglycemia-related anxiety affected your decision-making or performance during a competition and how you navigated and/or overcame those challenges, if at all?

Prompting Questions:

- Are there any specific support systems or resources that you find helpful in addressing your hyperglycemia-related anxiety and optimizing your diabetes management during competitions?

- How have you used any psychological/behavioral interventions or techniques, such as goal setting, visualization, and/or mindfulness, to manage hyperglycemia-related anxiety, if at all? If so, how have they influenced your diabetes management and performance outcomes?

- What other interventions, support, or technologies, if any, could be implemented to reduce the frequency of impact of hyperglycemia-related anxiety during competition for elite athletes with T1D, in general?

Transcript and Analysis

Interviews were recorded and transcribed using Microsoft Teams. A research team member (MA.F.) verified and anonymized the transcriptions. Recordings were deleted to preserve confidentiality. French meeting transcriptions were translated to English using a forward-backwards translation method.

Transcriptions were uploaded to MAXQDA (version 24, VERBI GmbH, Berlin, Germany) [24]. The beta AI Assist function was used to generate preliminary codes. Using an Interpretive Phenomenological Analysis approach, two independent researchers (A.K. and A.S.) reviewed and refined the codes to create the codebook, which was applied to the entire dataset. Overarching concepts, relationships, or sequences among the themes were identified and analyzed. A detailed essence description of participants' experiences and highlighted main themes was created. Study participants verified the essence description to complete the member-checking process. Once validated, revisions were made based

on feedback. Participants were provided with a 50\$ CAD electronic Amazon gift card or a donation in their name to a diabetes-specific charity of their choice.

Results

Ten elite athletes (5 males, and 5 females) were interviewed from November to December 2023. Participants had an average age of 25 ± 3 years, had a T1D duration of 12 ± 8 years, participated in 27 ± 19 competitions per year, and performed 12 ± 6 hours of training per week. Four participants were tier 3, and six participants were tier 4 athletes (tiers defined by [24]). Four participants used continuous subcutaneous insulin infusions (CSII) and six participants used multiple daily injections. All athletes used real-time continuous glucose monitoring (rtCGM) and its alerts/alarm feature in the last year. They originated from Canada, the United States, or the United Kingdom and self-reported as Caucasian. The athletes engaged in various sports, including speed skating, cross-country/track running, ice hockey, rugby, volleyball, basketball, and baseball.

Hyperglycemia in Elite Athletes with T1D

Hyperglycemia Symptoms

Participants reported experiencing a variety of hyperglycemia symptoms during both training and competition. These included irritability, muscle cramps, impatience, agitation, attention deficiency, excessive thirst, blurred vision, delayed reaction time, frequent urination, fatigue, abdominal pain, and shortness of breath. Elite athletes highlighted that certain symptoms had a more significant impact due to the rigorous demands of their training and competitive environments. For instance, delayed reaction time proved particularly detrimental during critical moments in competitions requiring quick reflexes. Maintaining focus over extended periods was notably challenging, and exertion levels exacerbated feelings of fatigue, affecting performance. Additionally, severe muscle cramps were a common issue that often required immediate attention to prevent complications during competitions.

Stress-Induced Hyperglycemia

Athletes reported a relationship between stress and hyperglycemia, particularly before and during competitions. A participant stated, “Before [competition], I have so much adrenaline that my BG skyrockets,” and during competition, “No matter what I do, the adrenaline gets going, and I could start at a perfect six and feel great. And then as the [game starts], you can see my numbers go up to 20 to 25.” These descriptions suggest that anticipatory stress and competitive environments contribute to acute BG elevations. Additionally, a participant noted, “I’m stressed because I see my BG not being optimal [...], and then I’ll be even more stressed [...] So, I’m more reactive than proactive.” This demonstrates the vicious cycle that the athletes reported between BG levels and HRA.

Hyperglycemia-Related Anxiety

Beyond the physical symptoms, hyperglycemia led to constant stress that affected the athletes' mental well-being, leading to HRA, “On a more psychological level, it’s a constant stress if [my BG] is not perfect or at the number I would want it to be for optimal performance.” The chronic nature of this stress was described as “in the background of your mind all the time.”

Additionally, fear of underperforming due to hyperglycemia added another layer of psychological strain, “In hyperglycemia, I don’t feel good. I don’t want to feel unwell during my sport and perform poorly or make mistakes that I wouldn’t normally make.” Feeling uncomfortable discussing it with teammates who cannot relate worsened the psychological impact for many, “You can’t really talk to a teammate about [HRA]. It’s not like it’s a pulled groin or a torn ligament that you can relate to most other people about.” Athletes expressed how stress affects their BG variation, emphasizing the need for targeted strategies. These strategies should aim to manage stress, thereby improving glycemic management and overall performance.

Strategies Currently Used to Prevent HRA

Elite athletes discussed their strategies for reducing hyperglycemia during competition, therefore limiting HRA.

1. *Insulin and Nutrition*

Athletes mentioned increasing basal insulin before a competition to prevent hyperglycemia. A participant stated, “I went from taking five units to eight units leading into that [competition], which is pretty substantial” to ensure normalized BG levels. Athletes also discussed increasing bolus insulin mid-game, as pre-competition adjustments were insufficient, highlighting the challenges of predicting insulin needs during competition, “I take more insulin because sometimes [my BG] continues to rise [mid-competition].”

Athletes stressed the importance of pre-planning meals and maintaining dietary consistency while being mindful of the glycemic index of foods. Many opted for complex carbohydrates to prevent rapid elevations; others focus on the timing and order of nutrient intake to control digestion rates, “Eating protein before carbs puts a blanket around your carbs, so you're not eating carbs on an empty stomach and digesting them on their own. Having a little bit more fat with it also slows down the digestion rate. You're not getting that [BG] spike all at one time.” Athletes also emphasized the importance of staying well-hydrated, highlighting its impact on mitigating their BG variability.

2. *Social Support Network*

Engaging with healthcare professionals (HCPs) was highlighted as crucial for minimizing HRA, “My family doctor makes appointments with me every two weeks and we go through all my [rtCGM] data [...] and if there's a time where my BG isn't ideal, it's like, ‘Hey, I really need to dial in [...] maybe instead of doing this, you need to do this.’” The involvement of endocrinologists was also discussed, with a participant sharing that their endocrinologist provided them with potential strategies based on another of their patients' experiences, “My endocrinologist is [a professional athlete's] endocrinologist. [...] I know that on the bench, he has a tablet that is directly connected to his sensor. As soon as he comes off the ice, he sees his BG automatically. If it's rising, falling,

he can control everything; it's all at his fingertips.” Athletes described the importance of consultations with trusted HCPs to optimize diabetes management.

Furthermore, the study highlighted the support of dietitians and mental performance coaches. Dietitians played an essential role in guiding dietary choices and offered insights into managing BG through strategic meal planning. Mental performance coaches contributed to psychologically managing diabetes, particularly in navigating competitive stress challenges. None of the athletes mentioned that their training staff provided assistance or had an adequate understanding of T1D.

Family and friends were also recognized as crucial support systems, providing emotional support and practical assistance in diabetes management, “My parents are a good outlet. [...] They get all my CGM data on their phone. If I see [my mom] text me at like [...] 11:00 pm and she's probably half asleep, I'm thinking, ‘I got to check my BG.’” These support systems contributed significantly to the athletes' well-being, thereby reducing HRA.

Additionally, peer support emerged as a valuable strategy, “One of my friends has T1D and he's a lifesaver, helped me a lot. He gives me some tips.” The exchange of insights among T1D peers provided unique support, as athletes drew on shared experiences to gain practical advice and emotional encouragement.

The study also acknowledged that following and interacting with influencers, celebrities, and professional athletes, who share their T1D experiences on social media helped to reduce HRA, “[A professional athlete] also has T1D, and he posts stuff on Instagram, so [...] sometimes I think, ‘Oh, I could try that.’”

3. *Technology*

Athletes unanimously highlighted rtCGMs' importance in improving their BG level awareness and adjustments during competitions. They stated, “It can help during competitions to predict how my [BG levels] will go” and “Constantly having [rtCGM] at my fingertips, it can tell

me exactly what I'm at and if I need to make any adjustments.” Two athletes mentioned that integrating rtCGM alerts into their daily routines was a crucial tool for preventive adjustments, allowing them to address BG variations before they become problematic.

Athletes highlighted the benefits of CSII for adjusting basal rates and making real-time adjustments, especially during training and competition, “I use a [CSII], and it really helps me [...]. If you're able to alleviate some decisions, that to me is very impactful to my psychological and physical well-being.” Furthermore, the integration of rtCGM with CSII technology emerged as a notably effective diabetes management approach. This combination addresses the dynamic interaction between CSII and rtCGM, offering athletes enhanced control and flexibility in managing their diabetes during various activities.

4. *Psychological Preparation*

Athletes highlighted the role of meditation in managing HRA, “I try to focus a lot on the mental side of meditating pre-game to avoid that huge adrenaline spike.” They specifically mentioned meditation as crucial for clearing the mind the night before their competition, “Meditation is a big thing. I always meditate the night before the [competition]. It helps relax my nervous system because there's a lot of anxiety about [competing].”

Additionally, athletes described the positive effects of mental preparation on BG stability, “I did mental preparation this year for the first time, and it was really cool. Stress raises your BG, and this year, [...] my BGs were much more stable.” This effect suggested a potential link between mental preparedness, reduced stress, and improved BG levels. They also stated, “Being more prepared, being more in control, being more comfortable – obviously, I'm less stressed, so it's sure that my BG rises less.”

Athletes also highlighted the efficacy of goal setting in mitigating HRA. However, they cautioned against having too many goals, as it can intensify anxiety and stress, “When you have 14 [goals] coming at you at once, it can seem overwhelming and amplify anxiety. When it's just one,

two or three [goals], it's a little bit easier.” Additionally, the importance of setting realistic goals was mentioned, “If you set unrealistic goals [...], it's really easy to get let down.”

Finally, athletes noted the importance of focusing on performance and avoiding additional stress, “I concentrate on my performance and kind of forget about diabetes during that time.” This performance-centric mindfulness approach helps them manage BG levels more effectively. Having self-awareness about the current circumstances is also essential to mitigate anxiety, “I'm high, I'm dealing with it, and trusting the insulin [...] I will come down [...] I can't do anything more just now other than focus on my game.”

5. *Routines*

On competition days, athletes emphasized implementing pre-established routines to predict BG variability better, “Having a game plan, an established routine before a game helps me and I try to stick to it.” This athlete also details their game-day routine, “On game days, I have a pre-established routine. I [...] always have the same breakfast and make the same smoothie with the same quantities [...] my goal is to minimize variability and create a sense of predictability in managing my BG levels,” which effectively reduced their HRA.

6. *Aerobic Exercise*

Athletes highlighted the significance of engaging in aerobic exercise before competition, as a valuable HRA management tool. One athlete mentioned incorporating long walks after meals and before a competition, perceiving a potential decrease in stress and subsequently BG levels, “If you're high, [it helps to] do a prolonged aerobic warm up. That'll probably bring you into range.”

Another athlete timed their workouts with periods in which they typically had lower BG levels, such as mornings. By aligning aerobic exercise routines with biological patterns, the athlete

leverages their body's natural responses to optimize BG control. The athlete stated that by knowing their “[BG] patterns, I try to work around them and use them to my advantage.”

7. *Sleep*

Athletes noted that insufficient or unrestful sleep could impair performance, thereby increasing anxiety and contributing to BG elevations the following day, “If I don't get enough sleep or I'm not properly rested, I find that [my BG] can spike.” Implementing structured bedtime routines to enhance sleep quality was also reported. They added, “I'll have herbal tea before I jump in the shower [...] then I'll stretch and meditate so that my body just has that rhythm [...] that's been a big help for me.” Late-night schedules and deviations from regular sleep patterns were identified as factors contributing to BG management challenges.

Athletes reported using natural sleep aids such as melatonin and magnesium to increase relaxation and improve sleep quality. However, challenges were identified such as experiencing morning foginess, which affected their performance during early-morning competitions, “Our [training] starts at 9:00 am, so I'm up at 5:30 to 6:00 am. The melatonin [...] has me in a fog through the morning. You want to feel sharp [...], you want to feel ready, especially when [every second] matters.” This underscores the importance of considering the timing and potential side effects of sleep aids in the context of athletic schedules.

Development of Strategies to Support Elite Athletes with HRA

1. *Social Support Network*

Given that there are few elite athletes with T1D, building social support networks can be challenging. A participant stated, “If I knew another athlete who has really tight control, like [a professional athlete], I'm sure he doesn't have these same problems as me because he has a team of

medical professionals.” This statement demonstrates the need for support networks to provide T1D athletes with a platform for shared experiences and insights. Another participant highlighted the importance of creating, “A community where you can exchange [...] with people who live the same reality as you [...] And I think that's something that might be missing.”

Additionally, providing family and friends with credible information may improve their support, “Your family members [...] or your partner, they may not understand [T1D].” The athlete added that developing support strategies for family and friends is essential to bridging existing gaps.

Further, teams and athletic organizations’ support staff should have access to targeted education to enhance their understanding of diabetes management, create an environment conducive to the successful integration of athletes with T1D, and reduce stigma. A participant stated, “It often happens that coaches ask me if I manage [my T1D] well. They don't necessarily ask more questions. I think it comes from ignorance [...] it's not that they don't care; it's that they don't know.” This comment underscores the need for education and training programs for coaching and support staff to ensure a comprehensive understanding of diabetes. They added, “it would help to know that the coaches are more aware of it. Maybe discussing it after a [competition] to know, ‘Okay, they understand that hyperglycemia had an impact on my performance,’ or ‘It's a challenge in my sport performance.’” Athletes preferred training staff to understand T1D instead of taking an active role in their management, “The support that, someone like a trainer could provide would be having certain tools accessible [to understand T1D] rather than [...] offering management tips.”

HCPs play an essential role in guiding athletes on diabetes management strategies and providing tailored advice. However, few HCPs have knowledge about the unique needs of elite athletes with T1D, let alone about HRA in this population.




2. Technology

Many athletes desired systems that automate insulin adjustments based on factors like exercise and carbohydrate intake. These technologies have the potential to impact psychological and physical well-being significantly, “It'd be great to have a closed-loop system where I don't have to put in how many carbs I'm eating. Or, like, if I'm working out, it's just able to adjust my insulin values [without manual adjustments].” However, current technologies often fall short of meeting their expectations. Furthermore, the affordability of existing technologies remained a concern, “I find [rtCGMs] to be a technology that would be worthwhile. But you know, it's expensive.”

Additionally, the discomfort and lack of trust associated with current CSII designs were highlighted. Some athletes refrained from using CSII due to concerns about the devices being large, bulky, and potentially unreliable, “I don't feel comfortable playing with it, with wires [...] I just wouldn't trust it to not fall off.” Thus, redesigning CSII to meet elite athletes' needs may make them more appealing.

Strategies are summarized in Figure 2.

Figure 2. Current and Future Strategies to Support Elite Athletes with T1D and HRA



Note: BG, blood glucose; CSII, continuous subcutaneous infusion; HRA, hyperglycemia-related anxiety; rtCGM, real-time continuous glucose monitor; T1D, type 1 diabetes

Discussion

This qualitative study is the first to explore HRA in elite athletes with T1D. Athletes currently use numerous strategies to reduce HRA, however, they are often insufficient. A recurring theme was the critical role of maintaining well-controlled BG levels to reduce HRA risk, but athletes highlighted the impact of competition on hyperglycemia due to competition-related physical and emotional stress likely increasing stress hormones and glycemia [26-30]. While guidelines recommend checking BG frequently to understand its direction and magnitude of change [12, 15], this strategy is not always easy to implement during competition.

Consistent with previous findings [14, 30], trial-and-error approaches were prevalent among athletes with T1D. The limited documentation of tactics leaves elite athletes with few strategies [14] and a desire for additional resources. These resources could include peer mentoring, support from training staff, and the use of medical devices [29]. Moreover, athletes expressed challenges associated with CSII usage during exercise, including physical interference with sporting activities, a sentiment expressed elsewhere [6].

In Riddell et al (2020) [6], a few strategies were outlined for competitive athletes with T1D who experience competition-related hyperglycemia. These strategies include cognitive techniques, pre-competition aerobic exercises, and administering temporary basal rate increases or partial bolus insulin to correct hyperglycemia. However, they did not address HRA, similar to other scientific literature. Further, our participants' experiences align with the suggestion from the *National Athletic Trainers' Association* [12] regarding consulting physicians for increased basal rates or small insulin boluses during periods of exercise-induced hyperglycemia. However, there are no evidence-based guidelines that physicians can use to guide their patients in this population. Thus, there is a need to develop resources to support elite athletes with T1D [15], particularly in subject areas such as HRA. Studies have shown that having access to specialized healthcare resources that are co-developed with patients can increase

confidence in diabetes management [31, 32]. Thus, future efforts should focus on developing education and awareness programs tailored to the unique needs of elite athletes with T1D, addressing the psychological and physiological challenges associated with competition-related hyperglycemia. Future strategies should be adaptive, accommodating each athlete's unique diabetes management needs [30].

Our study has several notable strengths and limitations. We implemented bracketing and member checking to increase reliability. The exclusion of participants with GAD limits this potential confounding variable. The broad spectrum of sports represented can be seen as a strength or a weakness; while it allowed us to gain a comprehensive understanding of HRA-related consequences and strategies, it limited the detailed exploration of specific challenges within each sport. Despite the small sample size of 10 participants, thematic saturation was achieved after approximately 5 or 6 interviews, with no new themes emerging in the subsequent interviews. This suggests that the sample size, while limited, was adequate for our qualitative analysis. Our study population, predominantly including Caucasian individuals from developed nations, may limit the generalizability of the results. Future research should consider larger, more diverse samples to enhance applicability.

Conclusion

In conclusion, addressing HRA in elite athletes with T1D involves refining current strategies, developing personalized tools, bridging support system gaps, enhancing education for athletes, training staff, peers, and HCPs, and acknowledging the unique needs of each athlete in the context of competition. Future research should aim to fill the existing void in resources and support mechanisms to optimize T1D management and performance in this population.

References

1. Steppel, J.H. and E.S. Horton, *Exercise in the management of type 1 diabetes mellitus*. Rev Endocr Metab Disord, 2003. 4(4): p. 355-60.

2. Hobbs, N., et al., *Observational Study of Glycemic Impact of Anticipatory and Early-Race Athletic Competition Stress in Type 1 Diabetes*. *Front Clin Diabetes Healthc*, 2022. **3**: p. 816316.
3. Yurkewicz, M., et al., *Diabetes and Sports: Managing Your Athlete With Type 1 Diabetes*. *Am J Lifestyle Med*, 2017. **11**(1): p. 58-63.
4. Brazeau, A.S., et al., *Barriers to physical activity among patients with type 1 diabetes*. *Diabetes Care*, 2008. **31**(11): p. 2108-9.
5. Moser, O., et al., *Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)*. *Diabetologia*, 2020. **63**(12): p. 2501-2520.
6. Riddell, M.C., et al., *The competitive athlete with type 1 diabetes*. *Diabetologia*, 2020. **63**(8): p. 1475-1490.
7. Hamlin, M.J., et al., *The Effect of Sleep Quality and Quantity on Athlete's Health and Perceived Training Quality*. *Front Sports Act Living*, 2021. **3**: p. 705650.
8. Poucher, Z.A., et al., *Prevalence of symptoms of common mental disorders among elite Canadian athletes*. *Psychology of Sport and Exercise*, 2021. **57**: p. 102018.
9. Riddell, M.C., et al., *Exercise management in type 1 diabetes: a consensus statement*. *Lancet Diabetes Endocrinol*, 2017. **5**(5): p. 377-390.
10. McGuire B, Dadah H, Oliver D. The effects of acute hyperglycaemia on sports and exercise performance in type 1 diabetes: A systematic review and meta-analysis. *J Sci Med Sport*. 2024 Feb;27(2):78-85. doi: 10.1016/j.jsams.2023.11.007. Epub 2023 Nov 21. PMID: 38030440.

11. Katz, A., et al., *Hyperglycemia-related anxiety during competition in an elite athlete with type 1 diabetes: A case report*. *Diabetes Metab*, 2023. **49**(5): p. 101476.
12. Jimenez, C.C., et al., *National athletic trainers' association position statement: management of the athlete with type 1 diabetes mellitus*. *J Athl Train*, 2007. **42**(4): p. 536-45.
13. Kahanovitz, L., P.M. Sluss, and S.J. Russell, *Type 1 Diabetes - A Clinical Perspective*. *Point Care*, 2017. **16**(1): p. 37-40.
14. Yardley, J.E., et al., *The "ups" and "downs" of a bike race in people with type 1 diabetes: dramatic differences in strategies and blood glucose responses in the Paris-to-Ancaster Spring Classic*. *Can J Diabetes*, 2015. **39**(2): p. 105-10.
15. Grightmire, B., W. Alkabbani, and J.-M. Gamble, *Peak performance: Putting type 1 diabetes management recommendations for athletes to the test*. *American Journal of Medicine Open*, 2022. **7**: p. 100011.
16. Paiement, K., et al., *Is Better Understanding of Management Strategies for Adults with Type 1 Diabetes Associated With a Lower Risk of Developing Hypoglycemia During and After Physical Activity?* *Can J Diabetes*, 2022. **46**(5): p. 526-534.
17. Nakhleh, A. and N. Shehadeh, *Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention*. *World J Diabetes*, 2021. **12**(12): p. 2036-2049.
18. Tong, A., P. Sainsbury, and J. Craig, *Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups*. *Int J Qual Health Care*, 2007. **19**(6): p. 349-57.
19. Spitzer, R.L., et al., *A brief measure for assessing generalized anxiety disorder: the GAD-7*. *Arch Intern Med*, 2006. **166**(10): p. 1092-7.
20. McKinney, J., et al., *Defining Athletes and Exercisers*. *Am J Cardiol*, 2019. **123**(3): p. 532-535.

21. Harris, P.A., et al., *The REDCap consortium: Building an international community of software platform partners*. J Biomed Inform, 2019. **95**: p. 103208.
22. Chan, Z., Y.-I. Fung, and W.-t. Chien, *Bracketing in Phenomenology: Only Undertaken in the Data Collection and Analysis Process*. Qualitative Report, 2013. **18**.
23. Singh, H., et al., *Assessing hyperglycemia avoidance in people with Type 1 diabetes*. Diabetes management, 2014. **4**: p. 263-271.
24. Kuckartz, U. and S. Rädiker, *Analyzing qualitative data with MAXQDA*. 2019: Springer.
25. McKay, A.K.A., et al., *Defining Training and Performance Caliber: A Participant Classification Framework*. Int J Sports Physiol Perform, 2022. **17**(2): p. 317-331.
26. van Weenen, E., et al., *Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: Retrospective, observational study over an entire competitive season*. Diabetes Obes Metab, 2023. **25**(9): p. 2616-2625.
27. Garrido Jimenez, P., et al., *Facial neuropathy secondary to cocaine use: an infrequent and refractory entity*. European Journal of Neurology, 2022. **29**(Supplement 1): p. 584.
28. Kelly, D., J.K. Hamilton, and M.C. Riddell, *Blood glucose levels and performance in a sports cAMP for adolescents with type 1 diabetes mellitus: a field study*. Int J Pediatr, 2010. **2010**.
29. Davis, J., et al., *2022 National Standards for Diabetes Self-Management Education and Support*. Diabetes Spectr, 2022. **35**(2): p. 137-149.
30. Dizon, S., et al., *Patient Perspectives on Managing Type 1 Diabetes During High-Performance Exercise: What Resources Do They Want?* Diabetes Spectr, 2019. **32**(1): p. 36-45.
31. Xie, L.F., et al., *Evaluation of Support, a self-guided online type 1 diabetes self-management education and support web application-a mixed methods study*. Digital Health, 2023. **9**: p. 20552076231204435.

32. Katz A, Roy-Fleming A, Housni A, Talbo MK, Haag S, Rabasa-Lhoret R, Brazeau AS. The Support-Pro Online Training Platform: Increasing Health Care Professionals' Confidence and Knowledge in Treating People Living With Type 1 Diabetes. *Diabetes Care*. 2024 May 23;dc240302. doi: 10.2337/dc24-0302. Epub ahead of print. PMID: 38781023.

Acknowledgments: The authors would like to thank the BETTER study group for guidance in establishing the research question and designing the platform. The authors would also like to thank the participants, Erik Sesbreno and the patient partner for their contributions to this project.

Funding and Assistance: This project was funded by Chaire J.A DeSève. A.K. received funding from the Canadian Graduate Scholarship-Master's Program. AS.B. is a fond de recherche du Québec en santé research scholar. All other authors received no financial support for the research, authorship, and/or publication of this article.

Conflicts of Interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.K., A.S., MA.F., J.K. A.H., and M.K.T. have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J.Y. has Dexcom and OneTouch in-kind research support. A.S.B. is a fond de recherche du Québec en santé research scholar and holds grants from CIHR, JDRF and Diabete Quebec. She also has speaker's fees from Dexcom and Abbott. R.R.L. has: 1. Research grants: Diabetes Canada, Astra-Zeneca, E Lilly, Cystic Fibrosis Canada, CIHR, FFRD, Janssen, JDRF, Merck, NIH, Novo-Nordisk, Societe Francophone du Diabete, Sanofi-Aventis, Vertex Pharmaceutical. 2. Consulting/advisory panel: Abbott, Astra-Zeneca, Bayer, Boehringer I, Dexcom, E Lilly, HLS therapeutics, INESSS, Insulet, Janssen, Medtronic, Merck, Novo- Nordisk, Pfizer, Sanofi-Aventis. 3. Honoraria for conferences: Abbott, Astra-Zeneca, Boehringer I, CPD Network, Dexcom, CMS Canadian Medical & Surgical Knowledge Translation Research group, E Lilly, Janssen, Medtronic, Merck, Novo-

Nordisk, Sanofi-Aventis, Tandem, Vertex Pharmaceutical. 4. Consumable gift (in kind): E Lilly, Medtronic. 5. Unrestricted grants for clinical and educational activities: Abbott, E Lilly, Medtronic, Merck, Novo Nordisk, Sanofi-Aventis. 6. Patent: T2D risk biomarkers, catheter life. 7. Purchase fees: E Lilly (artificial pancreas).

Author contributions and guarantor statement: A.K.: Conceptualization, methodology, project administration, protocol - original draft, protocol - review & editing, participation recruitment, interview conduction, formal analysis, visualization, writing - original draft, writing - review & editing. A.S.: Conceptualization, methodology, protocol - original draft, protocol - review & editing, interview conduction, formal analysis, visualization, writing - original draft, writing - review & editing. MA.F.: Interview conduction, writing - original draft, writing - review & editing. J.Y.: Conceptualization, protocol - review & editing, participation recruitment, writing - review & editing. J.K.: Conceptualization, methodology, protocol - review & editing, writing - review & editing. M.K.T: Protocol - review & editing, writing - review & editing. A.H.: Protocol - review & editing, writing - review & editing. R.R.L.: Conceptualization, protocol - review & editing, writing - review & editing, supervision. AS.B.: Conceptualization, protocol - review & editing, writing - review & editing, supervision. AS.B. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation: Presented at the 84th American Diabetes Association conference in June 2024 in Orlando, FL, USA.

Abbreviations:

BETTER: Behaviours, Therapies, Technologies, and Hypoglycemia Risk in T1D

BG: Blood glucose

CSII: Continuous Subcutaneous Insulin Infusion

GAD: Generalized Anxiety Disorder

HCP: Healthcare Professional

HRA: Hyperglycemia-Related Anxiety

IRCM: Montreal Clinical Research Institute

MDI: Multiple Daily Injection

PA: Physical Activity

REDCap: Research Electronic Data Capture

rtCGM: Real-Time Continuous Glucose Monitors

T1D: Type 1 Diabetes

Interview Discussion Guide

Probing Question 1:

- What impact, if any, has T1D had on your physical activity, in general?

Prompting Questions:

- How has T1D affected your capabilities as an athlete, if at all?
- How has T1D affected your ability to participate in physical activity, if at all?
- How does hypoglycemia impact physical activity and performance for you, if at all?
- How does your T1D management differ/not differ when participating in competition vs. training?

Probing Question 2:

- What impact, if any, has hyperglycemia had on your competition performance?

Prompting Questions:

- How does hyperglycemia during competitions impact your overall performance, if at all?
- How would you describe your physical reaction(s) if/when you experience hyperglycemia during competitions?
- How would you describe your psychological reaction(s) if/when you experience hyperglycemia during competitions?

Probing Question 3:

- What strategies, if any, do you use to prevent hyperglycemia and how effective do you find them to be?

Prompting Questions:

- What strategies or techniques do you currently use to prevent hyperglycemia during competitions (ex. changes in eating behaviors, medication, etc.), if any? How effective have they been for you, and what challenges have you encountered while implementing them?
- How do you prioritize between achieving optimal blood glucose levels and performing at your best during competitions? How do you find the right balance?
- What interventions, support, or technologies, if any, could be implemented to reduce the frequency of impact of hyperglycemia during competition for elite athletes with T1D, in general? This can include education, technology/CGM, nutrition, and/or insulin-related strategies.

Probing Question 4:

- How would you describe any hyperglycemia-related anxiety symptoms you may experience?

Prompting Questions:

- What physical, emotional, and/or behavioral symptoms do you experience during these times, if any? (e.g., racing heart, fast breathing)
- How does hyperglycemia-related anxiety impact your physical activity and/or performance during competition, if at all?
- How do your hyperglycemia-related anxiety symptoms influence your diabetes management strategies before, during, and after competitions, if at all?

Probing Question 5:


- Please describe any specific instances where hyperglycemia-related anxiety affected your decision-making or performance during a competition and how you navigated and/or overcame those challenges, if at all?

Prompting Questions:


- Are there any specific support systems or resources that you find helpful in addressing your hyperglycemia-related anxiety and optimizing your diabetes management during competitions?
- How have you used any psychological/behavioral interventions or techniques, such as goal setting, visualization, and/or mindfulness, to manage hyperglycemia-related anxiety, if at all? If so, how have they influenced your diabetes management and performance outcomes?
- What other interventions, support, or technologies, if any, could be implemented to reduce the frequency of impact of hyperglycemia-related anxiety during competition for elite athletes with T1D, in general?

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.19.24915888>; this version posted October 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. This article is a US Government work, and, as such, is in the public domain in the United States of America.

Strategies Currently Used to Prevent Hyperglycemia-Related Anxiety in Elite Athletes with T1D



medRxiv preprint doi: <https://doi.org/10.1101/2024.10.19.24315806>; this version posted October 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.



Development of Strategies to Support Elite Athletes with Hyperglycemia-Related Anxiety



Note: BG, blood glucose; CSII, continuous subcutaneous infusion; HRA, hyperglycemia-related anxiety; rtCGM, real-time continuous glucose monitor; T1D, type 1 diabetes

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.19.24315806>; this version posted October 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.